# Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis

> **NCT07101055** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jason A Roberts** · enrollment: 20 (estimated)

## Conditions studied

- End-Stage Kidney Disease (ESKD)

## Interventions

- **DRUG:** Letermovir 480 mg [PREVYMIS]

## Key facts

- **NCT ID:** NCT07101055
- **Lead sponsor:** Jason A Roberts
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-02
- **Final completion:** 2027-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101055, "Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07101055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*